<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568605</url>
  </required_header>
  <id_info>
    <org_study_id>UC-REB14-2464</org_study_id>
    <nct_id>NCT02568605</nct_id>
  </id_info>
  <brief_title>Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) is a condition where accumulation of fat in the
      liver leads to metabolic dysfunction. Currently there are no approved treatments for NAFLD.
      Part of the metabolic dysfunction may arise through changes in the gut microbiota. Prebiotic
      fibres have beneficial effects on glucose tolerance, body weight, and gut microbiota;
      therefore they may have potential as part of a dietary strategy for NAFLD treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to assess the effect of prebiotic fibre supplementation,
      in conjunction with diet-induced weight loss, on reduction in liver fat and injury.

      Primary Objective - determine the change in hepatic injury (fibrosis and inflammation) and
      hepatic fat (percent fat) over 6 months in NAFLD patients treated with prebiotic or placebo
      during weight loss.

      Secondary Objectives - determine the changes in appetite, body composition, glycemic and
      insulinemic responses, quality of life with prebiotic or placebo during weight loss, and
      examine mechanisms related to prebiotic-induced changes in gut microbiota and lipogenesis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Liver Fat</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed via MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Liver Fibrosis</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed via FibroScan (transient elastography)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Liver Injury</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed via Fibrotest Score (composite score from serum biochemical markers: alfa2-macroglobulin, apolipoproteinA1, total bilirubin, haptoglobin, gamma glutamyl transpeptidase, alanine aminotransferase)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Glucose Tolerance</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed via an oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycemic Control</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed via HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Subjective Appetite</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed via Subjective appetite ratings on a visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Satiety Hormones</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed in serum as pg/ml (Ghrelin, Glucagon-like peptide-1, Glucose-dependent insulinotropic polypeptide, leptin and Peptide tyrosine tyrosine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Composition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed via dual x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed via the Short Form-36v2 Health Survey questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Adherence</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed via adherence to prescribed versus measured energy intake assessed by food records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine mechanisms related to prebiotic-induced changes in gut microbiota, their metabolic byproducts, and de novo lipogenesis</measure>
    <time_frame>24 weeks</time_frame>
    <description>Via investigating gut microbiota shot-gun sequencing and measurement of volatile organic compounds and de novo lipogenesis using deuterium incorporation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Prebiotic Fibre</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will receive two 8g packets/day of prebiotic fibre to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive two 3g packets/day of maltodextrin to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weight Loss</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will be supported through Registered Dietitian visits to achieve approximately 10% weight loss.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotic fibre</intervention_name>
    <description>Oligofructose-enriched inulin (Synergy1)</description>
    <arm_group_label>Prebiotic Fibre</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight Loss</intervention_name>
    <description>All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.</description>
    <arm_group_label>Prebiotic Fibre</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Weight Loss</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects diagnosed with NAFLD on the basis of abnormal liver enzymes (ALT&gt;1.5x
             upper limit of normal) and ultrasonography

          -  Exclusion of other causes of liver disease including viral hepatitis and alcoholic
             liver disease

          -  Aspartate aminotransferase and alanine aminotransferase â‰¤10x upper limit of normal

          -  Patients with type 2 diabetes treated with diet and exercise alone or metformin

        Exclusion Criteria:

          -  Cirrhosis of the liver (FibroScan &gt;17.5 kilopascal or FibroTest &gt;0.8) or clinical
             features of cirrhosis.

          -  Alcohol consumption &gt;20g/day (2 standard drinks) in women or &gt; 30g/d (3 drinks) in men

          -  Alternate (e.g. TPN) or concomitant etiology for abnormal liver enzymes.

          -  History of decompensated liver disease including ascites, encephalopathy or variceal
             bleeding

          -  Concomitant use of any weight loss medication, previous bariatric or other intestinal
             surgery

          -  Presence of active infection, pregnancy or lactation

          -  Regular use of a probiotic or prebiotic supplement within 3 months prior to enrollment

          -  Antibiotic use within 3 months prior to enrollment

          -  Weight loss &gt;3 kg within preceding 3 months to enrollment

          -  Uncontrolled cardiovascular or respiratory disease, active malignancy, or chronic
             infections

          -  Use of agents such as vitamin E, omega-3 fatty acids or medications with evidence for
             effects on NAFLD (pioglitazone, Glucagon-like peptide-1 analogues, dipeptidyl
             peptidase IV inhibitors, ursodeoxycholic acid)

          -  Patients with type 2 diabetes where HbA1c is &gt;9%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raylene A Reimer, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raylene A Reimer, PhD, RD</last_name>
    <phone>403-220-8218</phone>
    <email>reimer@ucalgary.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raylene A Reimer, PhD, RD</last_name>
      <phone>403-220-8218</phone>
      <email>reimer@ucalgary.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2015</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Raylene Reimer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Dietary intervention</keyword>
  <keyword>Prebiotic fibre</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Obesity</keyword>
  <keyword>Liver fat</keyword>
  <keyword>Hepatic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

